# A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors

> **NCT06737731** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 300 (estimated)

## Conditions studied

- Malignant Solid Tumors

## Interventions

- **DRUG:** SHR-1681

## Key facts

- **NCT ID:** NCT06737731
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-21
- **Primary completion:** 2026-11
- **Final completion:** 2027-07
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06737731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06737731, "A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06737731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*